Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InfuSystems HoldingsINFU +5.22%85 EV-to-EBITDA is 10.28 as of Aug. 08, 2026, which is 38% below its 10-year median of 16.54. GuruFocus rates INFU with a GF Score™ of 85/100 and a GF Value™ of $9.25 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 512 Medical Devices & Instruments companies, InfuSystems Holdings ranks better than 68.36% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, InfuSystems Holdings's enterprise value is $271.1 Mil.
InfuSystems Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $26.4 Mil. Therefore, InfuSystems Holdings's EV-to-EBITDA for today is 10.28.
The historical rank and industry rank for InfuSystems Holdings's EV-to-EBITDA or its related term are showing as below:
INFU'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.17 Med: 16.54 Max: 55.98
Current: 10.28
During the past 13 years, the highest EV-to-EBITDA of InfuSystems Holdings was 55.98. The lowest was 6.17. And the median was 16.54.
INFU's EV-to-EBITDA is ranked better than 68.36% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs INFU: 10.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
InfuSystems Holdings's PE Ratio (TTM) for today is calculated as:
InfuSystems Holdings's share price for today is $12.49.
InfuSystems Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for InfuSystems Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, InfuSystems Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InfuSystems Holdings EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where InfuSystems Holdings's EV-to-EBITDA falls into.
InfuSystems Holdings's current Enterprise Value is $271.1 Mil.
InfuSystems Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InfuSystems Holdings (INFU) has a EV-to-EBITDA of 10.28 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on InfuSystems Holdings. This is 38% below median its historical median of 16.54. Over the past decade, InfuSystems Holdings' EV-to-EBITDA has ranged from 6.17 to 55.98. According to the industry distribution chart, InfuSystems Holdings ranks #162 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 31.6%.
Is InfuSystems Holdings' EV-to-EBITDA too high?
InfuSystems Holdings' current EV-to-EBITDA of 10.28 is 38% below median its 10-year median of 16.54. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 55.98. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.65. InfuSystems Holdings' value of 10.28 is 29.8% below this industry median. Based on the distribution chart, InfuSystems Holdings ranks #162 out of 512 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InfuSystems Holdings has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InfuSystems Holdings' EV-to-EBITDA compare to LUCD and QTRX?
According to the Medical Devices & Instruments industry distribution chart, InfuSystems Holdings ranks #162 out of 512 companies for EV-to-EBITDA. This puts InfuSystems Holdings in the upper half of its industry. The industry median EV-to-EBITDA is 14.65. InfuSystems Holdings' value of 10.28 is 29.8% below this benchmark. Historically, InfuSystems Holdings' own EV-to-EBITDA has ranged from 6.17 to 55.98 over the past decade. While the company's 10-year median is 16.54 vs. the industry median of 14.65, InfuSystems Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InfuSystems Holdings's current EV-to-EBITDA of 10.28 is 29.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on InfuSystems Holdings. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InfuSystems Holdings's current EV-to-EBITDA is 10.28, which is 38% below median its own 10-year median of 16.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InfuSystems Holdings stock overvalued right now?
Based on GuruFocus' analysis, InfuSystems Holdings (INFU) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.25, compared to a current price of $12.49 — trading 35% above its estimated fair value. The current EV-to-EBITDA is 10.28, which is 38% below median its 10-year median of 16.54 and 29.8% below the Medical Devices & Instruments industry median of 14.65. InfuSystems Holdings' overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For InfuSystems Holdings (INFU), the current EV-to-EBITDA is 10.28 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InfuSystems Holdings (INFU) Overvalued in 2026?
Based on GuruFocus' analysis, InfuSystems Holdings stock appears to be overvalued.
The current stock price of $12.49 is trading 35% above its estimated GF Value™ of $9.25.
GuruFocus considers InfuSystems Holdings to be Significantly Overvalued.
Key valuation signals for INFU:
EV-to-EBITDA: 10.28 (38% below median its 10-year median of 16.54)
GF Value™: $9.25 vs. price of $12.49 (35% above fair value)
Industry Position: 29.8% below the Medical Devices & Instruments median (#162 of 512)
No single metric tells the full story. See the INFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
85GF Score
Get the complete analysis for INFU
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INFU has been successfully added to your 
